GEM132: HYBN plans to start clinical testing in Europe this summer and to file an IND in the U.S. in October.

Hybridon Inc. (HYBN), Worcester, Mass. Product: GEM132, antisense agent Indication: Cytomegalovirus (CMV) infection in AIDS Status: HYBN plans to start clinical testing in Europe this summer and to fi...